Estrogen signalling and Alzheimer's disease: Decoding molecular mechanisms for therapeutic breakthrough
In females, Alzheimer's disease (AD) incidences increases as compared to males due to estrogen deficiency after menopause. Estrogen therapy is the mainstay therapy for menopause and associated complications. Estrogen, a hormone with multifaceted physiological functions, has been implicated in A...
Gespeichert in:
Veröffentlicht in: | The European journal of neuroscience 2024-07, Vol.60 (1), p.3466-3490 |
---|---|
Hauptverfasser: | , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 3490 |
---|---|
container_issue | 1 |
container_start_page | 3466 |
container_title | The European journal of neuroscience |
container_volume | 60 |
creator | Rishabh Rohilla, Manni Bansal, Seema Bansal, Nitin Chauhan, Samrat Sharma, Sheenam Goyal, Navjyoti Gupta, Sumeet |
description | In females, Alzheimer's disease (AD) incidences increases as compared to males due to estrogen deficiency after menopause. Estrogen therapy is the mainstay therapy for menopause and associated complications. Estrogen, a hormone with multifaceted physiological functions, has been implicated in AD pathophysiology. Estrogen plays a crucial role in amyloid precursor protein (APP) processing and overall neuronal health by regulating various factors such as brain‐derived neurotrophic factor (BDNF), intracellular calcium signalling, death domain‐associated protein (Daxx) translocation, glutamatergic excitotoxicity, Voltage‐Dependent Anion Channel, Insulin‐Like Growth Factor 1 Receptor, estrogen‐metabolising enzymes and apolipoprotein E (ApoE) protein polymorphisms. All these factors impact the physiology of postmenopausal women. Estrogen replacement therapies play an important treatment strategy to prevent AD after menopause. However, use of these therapies may lead to increased risks of breast cancer, venous thromboembolism and cardiovascular disease. Various therapeutic approaches have been used to mitigate the effects of estrogen on AD. These include hormone replacement therapy, Selective Estrogen Receptor Modulators (SERMs), Estrogen Receptor Beta (ERβ)‐Selective Agonists, Transdermal Estrogen Delivery, Localised Estrogen Delivery, Combination Therapies, Estrogen Metabolism Modulation and Alternative Estrogenic Compounds like genistein from soy, a notable phytoestrogen from plant sources. However, mechanism via which these approaches modulate AD in postmenopausal women has not been explained earlier thoroughly. Present review will enlighten all the molecular mechanisms of estrogen and estrogen replacement therapies in AD. Along‐with this, the association between estrogen, estrogen‐metabolising enzymes and ApoE protein polymorphisms will also be discussed in postmenopausal AD.
Estrogen plays an important role in maintaining various physiological functions of the women's body. Estrogen deficiency due to oxidative stress, hormonal disbalance and disturbance in molecular signalling pathways such as intracellular calcium, Daxx translocation, glutaminergic excitotoxicity, voltage dependent anion and insulin like growth factor 1 receptor leads to the development of neurodegenerative diseases including Alzheimer's disease (AD). Molecular signalling works by altering the expression of estrogen receptors such as ERα & ERβ and through estrogen response elements. Enormou |
doi_str_mv | 10.1111/ejn.16360 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3053976209</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3075798527</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3130-c59b689de95e4f78e4bef3481aca81f8be785526fa4b32c41e3ae3d05e4cd6063</originalsourceid><addsrcrecordid>eNp10EtLxDAUhuEgio6XhX9AAi7URTVpmjR1JzreEN0ouCtpetpmTJsxaRH99XYcdSF4Nmfz8C1ehHYpOabjncCsO6aCCbKCJjQRJMq4kKtoQjLOIknF8wbaDGFGCJEi4etog8k0FqlIJqieht67GjocTN0pa01XY9WV-Mx-NGBa8AcBlyaACnCKL0C7ciFaZ0EPVnncgm5UZ0IbcOU87hvwag5DbzQuPKiXvvFuqJtttFYpG2Dn-2-hp8vp4_l1dPdwdXN-dhdpRhmJNM8KIbMSMg5JlUpICqhYIqnSStJKFpBKzmNRqaRgsU4oMAWsJKPWpSCCbaHD5e7cu9cBQp-3JmiwVnXghpAzwlmWiphkI93_Q2du8GODhUp5mkkep6M6WirtXQgeqnzuTav8e05Jvqifj_Xzr_qj3fteHIoWyl_5k3sEJ0vwZiy8_7-UT2_vl5OfDyCPrw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3075798527</pqid></control><display><type>article</type><title>Estrogen signalling and Alzheimer's disease: Decoding molecular mechanisms for therapeutic breakthrough</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Rishabh ; Rohilla, Manni ; Bansal, Seema ; Bansal, Nitin ; Chauhan, Samrat ; Sharma, Sheenam ; Goyal, Navjyoti ; Gupta, Sumeet</creator><creatorcontrib>Rishabh ; Rohilla, Manni ; Bansal, Seema ; Bansal, Nitin ; Chauhan, Samrat ; Sharma, Sheenam ; Goyal, Navjyoti ; Gupta, Sumeet</creatorcontrib><description>In females, Alzheimer's disease (AD) incidences increases as compared to males due to estrogen deficiency after menopause. Estrogen therapy is the mainstay therapy for menopause and associated complications. Estrogen, a hormone with multifaceted physiological functions, has been implicated in AD pathophysiology. Estrogen plays a crucial role in amyloid precursor protein (APP) processing and overall neuronal health by regulating various factors such as brain‐derived neurotrophic factor (BDNF), intracellular calcium signalling, death domain‐associated protein (Daxx) translocation, glutamatergic excitotoxicity, Voltage‐Dependent Anion Channel, Insulin‐Like Growth Factor 1 Receptor, estrogen‐metabolising enzymes and apolipoprotein E (ApoE) protein polymorphisms. All these factors impact the physiology of postmenopausal women. Estrogen replacement therapies play an important treatment strategy to prevent AD after menopause. However, use of these therapies may lead to increased risks of breast cancer, venous thromboembolism and cardiovascular disease. Various therapeutic approaches have been used to mitigate the effects of estrogen on AD. These include hormone replacement therapy, Selective Estrogen Receptor Modulators (SERMs), Estrogen Receptor Beta (ERβ)‐Selective Agonists, Transdermal Estrogen Delivery, Localised Estrogen Delivery, Combination Therapies, Estrogen Metabolism Modulation and Alternative Estrogenic Compounds like genistein from soy, a notable phytoestrogen from plant sources. However, mechanism via which these approaches modulate AD in postmenopausal women has not been explained earlier thoroughly. Present review will enlighten all the molecular mechanisms of estrogen and estrogen replacement therapies in AD. Along‐with this, the association between estrogen, estrogen‐metabolising enzymes and ApoE protein polymorphisms will also be discussed in postmenopausal AD.
Estrogen plays an important role in maintaining various physiological functions of the women's body. Estrogen deficiency due to oxidative stress, hormonal disbalance and disturbance in molecular signalling pathways such as intracellular calcium, Daxx translocation, glutaminergic excitotoxicity, voltage dependent anion and insulin like growth factor 1 receptor leads to the development of neurodegenerative diseases including Alzheimer's disease (AD). Molecular signalling works by altering the expression of estrogen receptors such as ERα & ERβ and through estrogen response elements. Enormous strategies such as hormone replacement therapy, SSRMs, COMT inhibitors and ERβ agonists can be used to prevent estrogen depletion associated AD.</description><identifier>ISSN: 0953-816X</identifier><identifier>ISSN: 1460-9568</identifier><identifier>EISSN: 1460-9568</identifier><identifier>DOI: 10.1111/ejn.16360</identifier><identifier>PMID: 38726764</identifier><language>eng</language><publisher>France: Wiley Subscription Services, Inc</publisher><subject>Alzheimer Disease - drug therapy ; Alzheimer Disease - metabolism ; Alzheimer's disease ; Amyloid precursor protein ; Animals ; Apolipoprotein E ; Brain-derived neurotrophic factor ; Calcium (intracellular) ; Calcium channels (voltage-gated) ; Calcium signalling ; Cardiovascular diseases ; Daxx protein ; Enzymes ; estrogen ; Estrogen receptors ; estrogen receptors alpha and beta ; Estrogen Replacement Therapy - methods ; Estrogens ; Estrogens - metabolism ; Excitotoxicity ; Female ; Genistein ; Glutamatergic transmission ; Hormone replacement therapy ; Humans ; Intracellular signalling ; Menopause ; Molecular modelling ; molecular signalling ; Neurodegenerative diseases ; Neuromodulation ; Pathophysiology ; Phytoestrogens ; Post-menopause ; Protein transport ; Proteins ; Selective estrogen receptor modulators ; Signal Transduction - drug effects ; therapeutic target ; Xenoestrogens</subject><ispartof>The European journal of neuroscience, 2024-07, Vol.60 (1), p.3466-3490</ispartof><rights>2024 Federation of European Neuroscience Societies and John Wiley & Sons Ltd.</rights><rights>2024 Federation of European Neuroscience Societies and John Wiley & Sons Ltd</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c3130-c59b689de95e4f78e4bef3481aca81f8be785526fa4b32c41e3ae3d05e4cd6063</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fejn.16360$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fejn.16360$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,778,782,1414,27907,27908,45557,45558</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38726764$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Rishabh</creatorcontrib><creatorcontrib>Rohilla, Manni</creatorcontrib><creatorcontrib>Bansal, Seema</creatorcontrib><creatorcontrib>Bansal, Nitin</creatorcontrib><creatorcontrib>Chauhan, Samrat</creatorcontrib><creatorcontrib>Sharma, Sheenam</creatorcontrib><creatorcontrib>Goyal, Navjyoti</creatorcontrib><creatorcontrib>Gupta, Sumeet</creatorcontrib><title>Estrogen signalling and Alzheimer's disease: Decoding molecular mechanisms for therapeutic breakthrough</title><title>The European journal of neuroscience</title><addtitle>Eur J Neurosci</addtitle><description>In females, Alzheimer's disease (AD) incidences increases as compared to males due to estrogen deficiency after menopause. Estrogen therapy is the mainstay therapy for menopause and associated complications. Estrogen, a hormone with multifaceted physiological functions, has been implicated in AD pathophysiology. Estrogen plays a crucial role in amyloid precursor protein (APP) processing and overall neuronal health by regulating various factors such as brain‐derived neurotrophic factor (BDNF), intracellular calcium signalling, death domain‐associated protein (Daxx) translocation, glutamatergic excitotoxicity, Voltage‐Dependent Anion Channel, Insulin‐Like Growth Factor 1 Receptor, estrogen‐metabolising enzymes and apolipoprotein E (ApoE) protein polymorphisms. All these factors impact the physiology of postmenopausal women. Estrogen replacement therapies play an important treatment strategy to prevent AD after menopause. However, use of these therapies may lead to increased risks of breast cancer, venous thromboembolism and cardiovascular disease. Various therapeutic approaches have been used to mitigate the effects of estrogen on AD. These include hormone replacement therapy, Selective Estrogen Receptor Modulators (SERMs), Estrogen Receptor Beta (ERβ)‐Selective Agonists, Transdermal Estrogen Delivery, Localised Estrogen Delivery, Combination Therapies, Estrogen Metabolism Modulation and Alternative Estrogenic Compounds like genistein from soy, a notable phytoestrogen from plant sources. However, mechanism via which these approaches modulate AD in postmenopausal women has not been explained earlier thoroughly. Present review will enlighten all the molecular mechanisms of estrogen and estrogen replacement therapies in AD. Along‐with this, the association between estrogen, estrogen‐metabolising enzymes and ApoE protein polymorphisms will also be discussed in postmenopausal AD.
Estrogen plays an important role in maintaining various physiological functions of the women's body. Estrogen deficiency due to oxidative stress, hormonal disbalance and disturbance in molecular signalling pathways such as intracellular calcium, Daxx translocation, glutaminergic excitotoxicity, voltage dependent anion and insulin like growth factor 1 receptor leads to the development of neurodegenerative diseases including Alzheimer's disease (AD). Molecular signalling works by altering the expression of estrogen receptors such as ERα & ERβ and through estrogen response elements. Enormous strategies such as hormone replacement therapy, SSRMs, COMT inhibitors and ERβ agonists can be used to prevent estrogen depletion associated AD.</description><subject>Alzheimer Disease - drug therapy</subject><subject>Alzheimer Disease - metabolism</subject><subject>Alzheimer's disease</subject><subject>Amyloid precursor protein</subject><subject>Animals</subject><subject>Apolipoprotein E</subject><subject>Brain-derived neurotrophic factor</subject><subject>Calcium (intracellular)</subject><subject>Calcium channels (voltage-gated)</subject><subject>Calcium signalling</subject><subject>Cardiovascular diseases</subject><subject>Daxx protein</subject><subject>Enzymes</subject><subject>estrogen</subject><subject>Estrogen receptors</subject><subject>estrogen receptors alpha and beta</subject><subject>Estrogen Replacement Therapy - methods</subject><subject>Estrogens</subject><subject>Estrogens - metabolism</subject><subject>Excitotoxicity</subject><subject>Female</subject><subject>Genistein</subject><subject>Glutamatergic transmission</subject><subject>Hormone replacement therapy</subject><subject>Humans</subject><subject>Intracellular signalling</subject><subject>Menopause</subject><subject>Molecular modelling</subject><subject>molecular signalling</subject><subject>Neurodegenerative diseases</subject><subject>Neuromodulation</subject><subject>Pathophysiology</subject><subject>Phytoestrogens</subject><subject>Post-menopause</subject><subject>Protein transport</subject><subject>Proteins</subject><subject>Selective estrogen receptor modulators</subject><subject>Signal Transduction - drug effects</subject><subject>therapeutic target</subject><subject>Xenoestrogens</subject><issn>0953-816X</issn><issn>1460-9568</issn><issn>1460-9568</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp10EtLxDAUhuEgio6XhX9AAi7URTVpmjR1JzreEN0ouCtpetpmTJsxaRH99XYcdSF4Nmfz8C1ehHYpOabjncCsO6aCCbKCJjQRJMq4kKtoQjLOIknF8wbaDGFGCJEi4etog8k0FqlIJqieht67GjocTN0pa01XY9WV-Mx-NGBa8AcBlyaACnCKL0C7ciFaZ0EPVnncgm5UZ0IbcOU87hvwag5DbzQuPKiXvvFuqJtttFYpG2Dn-2-hp8vp4_l1dPdwdXN-dhdpRhmJNM8KIbMSMg5JlUpICqhYIqnSStJKFpBKzmNRqaRgsU4oMAWsJKPWpSCCbaHD5e7cu9cBQp-3JmiwVnXghpAzwlmWiphkI93_Q2du8GODhUp5mkkep6M6WirtXQgeqnzuTav8e05Jvqifj_Xzr_qj3fteHIoWyl_5k3sEJ0vwZiy8_7-UT2_vl5OfDyCPrw</recordid><startdate>202407</startdate><enddate>202407</enddate><creator>Rishabh</creator><creator>Rohilla, Manni</creator><creator>Bansal, Seema</creator><creator>Bansal, Nitin</creator><creator>Chauhan, Samrat</creator><creator>Sharma, Sheenam</creator><creator>Goyal, Navjyoti</creator><creator>Gupta, Sumeet</creator><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>7QR</scope><scope>7TK</scope><scope>8FD</scope><scope>FR3</scope><scope>P64</scope><scope>7X8</scope></search><sort><creationdate>202407</creationdate><title>Estrogen signalling and Alzheimer's disease: Decoding molecular mechanisms for therapeutic breakthrough</title><author>Rishabh ; Rohilla, Manni ; Bansal, Seema ; Bansal, Nitin ; Chauhan, Samrat ; Sharma, Sheenam ; Goyal, Navjyoti ; Gupta, Sumeet</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3130-c59b689de95e4f78e4bef3481aca81f8be785526fa4b32c41e3ae3d05e4cd6063</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Alzheimer Disease - drug therapy</topic><topic>Alzheimer Disease - metabolism</topic><topic>Alzheimer's disease</topic><topic>Amyloid precursor protein</topic><topic>Animals</topic><topic>Apolipoprotein E</topic><topic>Brain-derived neurotrophic factor</topic><topic>Calcium (intracellular)</topic><topic>Calcium channels (voltage-gated)</topic><topic>Calcium signalling</topic><topic>Cardiovascular diseases</topic><topic>Daxx protein</topic><topic>Enzymes</topic><topic>estrogen</topic><topic>Estrogen receptors</topic><topic>estrogen receptors alpha and beta</topic><topic>Estrogen Replacement Therapy - methods</topic><topic>Estrogens</topic><topic>Estrogens - metabolism</topic><topic>Excitotoxicity</topic><topic>Female</topic><topic>Genistein</topic><topic>Glutamatergic transmission</topic><topic>Hormone replacement therapy</topic><topic>Humans</topic><topic>Intracellular signalling</topic><topic>Menopause</topic><topic>Molecular modelling</topic><topic>molecular signalling</topic><topic>Neurodegenerative diseases</topic><topic>Neuromodulation</topic><topic>Pathophysiology</topic><topic>Phytoestrogens</topic><topic>Post-menopause</topic><topic>Protein transport</topic><topic>Proteins</topic><topic>Selective estrogen receptor modulators</topic><topic>Signal Transduction - drug effects</topic><topic>therapeutic target</topic><topic>Xenoestrogens</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Rishabh</creatorcontrib><creatorcontrib>Rohilla, Manni</creatorcontrib><creatorcontrib>Bansal, Seema</creatorcontrib><creatorcontrib>Bansal, Nitin</creatorcontrib><creatorcontrib>Chauhan, Samrat</creatorcontrib><creatorcontrib>Sharma, Sheenam</creatorcontrib><creatorcontrib>Goyal, Navjyoti</creatorcontrib><creatorcontrib>Gupta, Sumeet</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Chemoreception Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>The European journal of neuroscience</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Rishabh</au><au>Rohilla, Manni</au><au>Bansal, Seema</au><au>Bansal, Nitin</au><au>Chauhan, Samrat</au><au>Sharma, Sheenam</au><au>Goyal, Navjyoti</au><au>Gupta, Sumeet</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Estrogen signalling and Alzheimer's disease: Decoding molecular mechanisms for therapeutic breakthrough</atitle><jtitle>The European journal of neuroscience</jtitle><addtitle>Eur J Neurosci</addtitle><date>2024-07</date><risdate>2024</risdate><volume>60</volume><issue>1</issue><spage>3466</spage><epage>3490</epage><pages>3466-3490</pages><issn>0953-816X</issn><issn>1460-9568</issn><eissn>1460-9568</eissn><abstract>In females, Alzheimer's disease (AD) incidences increases as compared to males due to estrogen deficiency after menopause. Estrogen therapy is the mainstay therapy for menopause and associated complications. Estrogen, a hormone with multifaceted physiological functions, has been implicated in AD pathophysiology. Estrogen plays a crucial role in amyloid precursor protein (APP) processing and overall neuronal health by regulating various factors such as brain‐derived neurotrophic factor (BDNF), intracellular calcium signalling, death domain‐associated protein (Daxx) translocation, glutamatergic excitotoxicity, Voltage‐Dependent Anion Channel, Insulin‐Like Growth Factor 1 Receptor, estrogen‐metabolising enzymes and apolipoprotein E (ApoE) protein polymorphisms. All these factors impact the physiology of postmenopausal women. Estrogen replacement therapies play an important treatment strategy to prevent AD after menopause. However, use of these therapies may lead to increased risks of breast cancer, venous thromboembolism and cardiovascular disease. Various therapeutic approaches have been used to mitigate the effects of estrogen on AD. These include hormone replacement therapy, Selective Estrogen Receptor Modulators (SERMs), Estrogen Receptor Beta (ERβ)‐Selective Agonists, Transdermal Estrogen Delivery, Localised Estrogen Delivery, Combination Therapies, Estrogen Metabolism Modulation and Alternative Estrogenic Compounds like genistein from soy, a notable phytoestrogen from plant sources. However, mechanism via which these approaches modulate AD in postmenopausal women has not been explained earlier thoroughly. Present review will enlighten all the molecular mechanisms of estrogen and estrogen replacement therapies in AD. Along‐with this, the association between estrogen, estrogen‐metabolising enzymes and ApoE protein polymorphisms will also be discussed in postmenopausal AD.
Estrogen plays an important role in maintaining various physiological functions of the women's body. Estrogen deficiency due to oxidative stress, hormonal disbalance and disturbance in molecular signalling pathways such as intracellular calcium, Daxx translocation, glutaminergic excitotoxicity, voltage dependent anion and insulin like growth factor 1 receptor leads to the development of neurodegenerative diseases including Alzheimer's disease (AD). Molecular signalling works by altering the expression of estrogen receptors such as ERα & ERβ and through estrogen response elements. Enormous strategies such as hormone replacement therapy, SSRMs, COMT inhibitors and ERβ agonists can be used to prevent estrogen depletion associated AD.</abstract><cop>France</cop><pub>Wiley Subscription Services, Inc</pub><pmid>38726764</pmid><doi>10.1111/ejn.16360</doi><tpages>25</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0953-816X |
ispartof | The European journal of neuroscience, 2024-07, Vol.60 (1), p.3466-3490 |
issn | 0953-816X 1460-9568 1460-9568 |
language | eng |
recordid | cdi_proquest_miscellaneous_3053976209 |
source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
subjects | Alzheimer Disease - drug therapy Alzheimer Disease - metabolism Alzheimer's disease Amyloid precursor protein Animals Apolipoprotein E Brain-derived neurotrophic factor Calcium (intracellular) Calcium channels (voltage-gated) Calcium signalling Cardiovascular diseases Daxx protein Enzymes estrogen Estrogen receptors estrogen receptors alpha and beta Estrogen Replacement Therapy - methods Estrogens Estrogens - metabolism Excitotoxicity Female Genistein Glutamatergic transmission Hormone replacement therapy Humans Intracellular signalling Menopause Molecular modelling molecular signalling Neurodegenerative diseases Neuromodulation Pathophysiology Phytoestrogens Post-menopause Protein transport Proteins Selective estrogen receptor modulators Signal Transduction - drug effects therapeutic target Xenoestrogens |
title | Estrogen signalling and Alzheimer's disease: Decoding molecular mechanisms for therapeutic breakthrough |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-16T11%3A59%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Estrogen%20signalling%20and%20Alzheimer's%20disease:%20Decoding%20molecular%20mechanisms%20for%20therapeutic%20breakthrough&rft.jtitle=The%20European%20journal%20of%20neuroscience&rft.au=Rishabh&rft.date=2024-07&rft.volume=60&rft.issue=1&rft.spage=3466&rft.epage=3490&rft.pages=3466-3490&rft.issn=0953-816X&rft.eissn=1460-9568&rft_id=info:doi/10.1111/ejn.16360&rft_dat=%3Cproquest_cross%3E3075798527%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3075798527&rft_id=info:pmid/38726764&rfr_iscdi=true |